CervoMed Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 15

Employees

  • Stock Symbol
  • CRVO

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $9.38
  • (As of Tuesday Closing)

CervoMed General Information

Description

CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Contact Information

Website
www.cervomed.com
Formerly Known As
EIP Pharma
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 20 Park Plaza
  • Suite 424
  • Boston, MA 02116
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Life Sciences
Corporate Office
  • 20 Park Plaza
  • Suite 424
  • Boston, MA 02116
  • United States
+1 (617)

CervoMed Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CervoMed Stock Performance

As of 29-Apr-2025, CervoMed’s stock price is $9.38. Its current market cap is $81.6M with 8.7M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.38 $9.15 $1.80 - $25.69 $81.6M 8.7M 4.64M -$2.02

CervoMed Financials Summary

As of 31-Dec-2024, CervoMed has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV (27,343) (27,343) 32,872 (15,544)
Revenue 0 0 0 0
EBITDA (18,228) (18,228) (2,391) (5,865)
Net Income (16,291) (16,291) (2,172) (5,803)
Total Assets 43,082 43,082 9,973 4,158
Total Debt 0 0 0 12,414
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CervoMed Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CervoMed‘s full profile, request access.

Request a free trial

CervoMed Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore CervoMed‘s full profile, request access.

Request a free trial

CervoMed Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologi
Drug Discovery
Boston, MA
15 As of 2024

Newton, MA
 

Clarksville, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CervoMed Competitors (24)

One of CervoMed’s 24 competitors is Pinteon Therapeutics, a Venture Capital-Backed company based in Newton, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pinteon Therapeutics Venture Capital-Backed Newton, MA
NeuroNascent Venture Capital-Backed Clarksville, MD
Minerva Neurosciences Formerly VC-backed Burlington, MA
Asceneuron Venture Capital-Backed Lausanne, Switzerland
Alzheon Venture Capital-Backed Framingham, MA
You’re viewing 5 of 24 competitors. Get the full list »

CervoMed Patents

  • 50

    Total Documents Applications and Grants

  • Total Patents Families

  • 29

    Granted

  • 16

    Pending

  • Expiring in next 12 mo

CervoMed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4426309-A1 Treatment of a selective population of patients having dementia with lewy bodies Pending 05-Nov-2021
CA-3234513-A1 Treatment of a selective population of patients having dementia with lewy bodies Pending 05-Nov-2021
AU-2022380947-A1 Treatment of a selective population of patients having dementia with lewy bodies Pending 05-Nov-2021
EP-4240486-A1 Treatment of gait dysfunction in neurodegenerative disease Pending 06-Nov-2020
AU-2021374995-A1 Treatment of gait dysfunction in neurodegenerative disease Pending 06-Nov-2020 A61K31/519
To view CervoMed’s complete patent history, request access »

CervoMed Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CervoMed Acquisitions (1)

CervoMed’s most recent deal was a Merger/Acquisition with Diffusion Pharmaceuticals. The deal was made on 16-Aug-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Diffusion Pharmaceuticals 16-Aug-2023 Merger/Acquisition Biotechnology
To view CervoMed’s complete acquisitions history, request access »

CervoMed FAQs

  • When was CervoMed founded?

    CervoMed was founded in 2014.

  • Where is CervoMed headquartered?

    CervoMed is headquartered in Boston, MA.

  • What is the size of CervoMed?

    CervoMed has 15 total employees.

  • What industry is CervoMed in?

    CervoMed’s primary industry is Drug Discovery.

  • Is CervoMed a private or public company?

    CervoMed is a Public company.

  • What is CervoMed’s stock symbol?

    The ticker symbol for CervoMed is CRVO.

  • What is the current stock price of CervoMed?

    As of 29-Apr-2025 the stock price of CervoMed is $9.38.

  • What is the current market cap of CervoMed?

    The current market capitalization of CervoMed is $81.6M.

  • Who are CervoMed’s competitors?

    Pinteon Therapeutics, NeuroNascent, Minerva Neurosciences, Asceneuron, and Alzheon are some of the 24 competitors of CervoMed.

  • What is CervoMed’s annual earnings per share (EPS)?

    CervoMed’s EPS for 12 months was -$2.02.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »